Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

Blood

Volumn 114, Issue 9, 2009, Pages 1729-1735

  Kumar, Shaji ^a   Giralt, Sergio ^b   Stadtmauer, Edward A ^c   Harousseau, Jean L ^d   Palumbo, Antonio ^e   Bensinger, William ^f   Comenzo, Raymond L ^g   Lentzsch, Suzanne ^h   Munshi, Nikhil ⁱ   Niesvizky, Ruben ^j   Miguel, Jesus San ^k   Ludwig, Heinz ^l   Bergsagel, Leif ^a   Blade, Joan ^m   Lonial, Sagar ⁿ   Anderson, Kenneth C ⁱ   Tosi, Patrizia ^o   Sonneveld, Pieter ^p   Sezer, Orhan ^q   Vesole, David ^r   Cavo, Michele ^s   Einsele, Hermann ^t   Richardson, Paul G ⁱ   Durie, Brian G M ^u   Rajkumar, S Vincent ^a   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INSTITUT DE BIOLOGIE   (France)

^e UNIVERSITY OF TURIN   (Italy)

^f Fred Hutchinson Cancer Research Center   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l WILHELMINEN HOSPITAL   (Austria)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q HUMBOLDT UNIVERSITY   (Germany)

^r LOYOLA UNIVERSITY CHICAGO   (United States)

^s Institute of Hematology and Medical Oncology Seragnoli   (Italy)

^t UNIVERSITY OF WÜRZBURG   (Germany)

^u CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PYRAZINE DERIVATIVE;

ALKYLATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELL MOTILITY; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL; ARTICLE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; ONCOLOGY; STEM CELL MOBILIZATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEDICAL ONCOLOGY; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 70349260793     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-205013     Document Type: Review

References (65)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97. (Pubitemid 26240110)
2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929-936. (Pubitemid 46638847)
3. Bladé J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755-3759. (Pubitemid 41739009)
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883. (Pubitemid 36532313)
5. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227-9233. (Pubitemid 46260178)
6. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multi-center sequential randomized clinical trial. Blood. 1998;92:3131-3136. (Pubitemid 28492319)
7. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate- dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052-3057. (Pubitemid 39507119)
8. Fermand JP, Ravaud P, Chevret S, et al. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): results of a prospective randomized trial [abstract]. Blood. 1996;88(suppl 1):685a.
9. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436. (Pubitemid 46630462)
10. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323. (Pubitemid 35266292)
11. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050-4053.
12. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol (ASCo Annual Meeting Abstracts). 2007;25(18S):LBA8025.
13. Richardson P, Chanan-Khan A, Schlossman R, et al. A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy [abstract]. Blood (ASH Annual Meeting Abstracts). 2005;106:2548.
14. Richardson P, Jagannath S, Raje N, et al. Lenalidomide, Bortezomib, and dexamethasone (Rev/ Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:187.
15. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436. (Pubitemid 46630462)
16. Rajkumar SV, Jacobus S, Callander N, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome with primary therapy and with stem cell transplantation [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26: 8504.
17. Harousseau JL, Mathiot C, Attal M, et al. Bortezomib/ dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26: 8505.
18. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-39. (Pubitemid 40967171)
19. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:77.
20. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase iii trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:653.
21. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783. (Pubitemid 40904528)
22. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108:3289-3294. (Pubitemid 44776865)
23. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805-1810.
24. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma [see comment]. N Engl J Med. 2003;349:2495-2502. (Pubitemid 38010075)
25. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol. 1999;16:245-254. (Pubitemid 30055713)
26. de la Rubia J, Blade J, Lahuerta JJ, et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma: results of the Spanish Myeloma Group (GEM) Study. Haematologica. 2006;91:621-627. (Pubitemid 43799457)
27. Boccadoro M, Palumbo A, Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica. 2002;87:846-850. (Pubitemid 34851555)
28. Jansen J, Thompson J, Dugan M, et al. Impaired PBPC collection in patients with myeloma after high-dose melphalan. Cytotherapy. 2004;6:498-504. (Pubitemid 39433584)
29. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547-2555.
30. Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242-247. (Pubitemid 32151178)
31. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413-423. (Pubitemid 36241497)
32. Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant. 1997;20: 211-217. (Pubitemid 27361913)
33. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035-2042. (Pubitemid 47299979)
34. Arora M, Burns LJ, Barker JN, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2004;10:395-404. (Pubitemid 38647288)
35. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy. 2007;9:539-547. (Pubitemid 47457005)
36. Lévesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111:187-196. (Pubitemid 36105917)
37. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4:72-77. (Pubitemid 28133082)
38. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-2730. (Pubitemid 37248839)
39. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non- Hodgkin's lymphoma. J Clin Oncol. 2004;22: 1095-1102. (Pubitemid 41095043)
40. DiPersio J, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, doubleblind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110:445.
41. Rajkumar SV, Rosinol L, Hussein M, et al. Multi-center, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171-2177.
42. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124-127. (Pubitemid 351156161)
43. Lacy M, Gertz M, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179-1184. (Pubitemid 47502875)
44. Kumar S, Hayman SR, Buadi FK, et al. Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma. [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:190.
45. Richardson PG, Lonial S, Jakubowiak A, et al. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): a phase I/II study [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26:8520.
46. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/ dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111:1101-1109. (Pubitemid 351213388)
47. Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25:4452-4458. (Pubitemid 350013852)
48. Kumar S, Hayman S, Buadi F, et al. Phase II trial of lenalidomide (RevlimidTM) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:91.
49. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23:1337-1341.
50. Kumar S, Flinn IW, Noga SJ, et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center EVOLUTION Study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:93.
51. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase i/ii study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:92.
52. Cavo M, Tacchetti P, Patriarca F, et al. Superior complete response rate and progression-free survival after autologous transplantation with upfront velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:158.
53. Rosinol L, Cibeira MT, Martinez J, et al. Thalidomide/ dexamethasone (TD) vs. bortezomib (Velcade(R))/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade(R) as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): first results of a prospective phase III PETHEMA/Gem Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:654.
54. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007; 21:1294-1299. (Pubitemid 46831819)
55. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008;22:1280-1281; author reply: 1281-1282. (Pubitemid 351773154)
56. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008;22:1282-1284. (Pubitemid 351833805)
57. Kumar S, Lacy M, Dispenzieri A, et al. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:3467.
58. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14:795-798. (Pubitemid 351773154)
59. Cook RJ, Vogl D, Mangan PA, et al. Lenalidomide and stem cell collection in patients with multiple myeloma [abstract]. J Clin Oncol (Meeting Abstracts). 2008;26:8547.
60. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15: 718-723.
61. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776-783. (Pubitemid 40904528)
62. Goldschmidt H, Lokhorst HM, Bertsch U, et al. Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bortezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:3470.
63. Bensinger W, Jagannath S, Vescio R, et al. A phase II study of bortezomib (Velcade (R)), cyclophosphamide (cytoxan(R)), thalidomide (thalomid(R)) and dexamethasone as first-line therapy for multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:94.
64. Koh KR, Janz M, Mapara MY, et al. Immuno-modulatory derivative of thalidomide (IMiD CC- 4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105:3833-3840. (Pubitemid 40656125)
65. Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006; 107:3098-3105.